Generic Medicine Info
Indications and Dosage
Chronic hyponatraemia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Adult: Initially, 900-1,200 mg daily in divided doses. Maintenance: 600-900 mg daily in divided doses.
Child: Not recommended for childn <12 yr.

Susceptible infections
Adult: 600 mg daily in 2 or 4 divided doses.
Child: Not recommended for childn <12 yr.

Atypical pneumonia
Adult: 900 mg daily in 3 divided doses for 6 days.
Child: Not recommended for childn <12 yr.
Hepatic Impairment
Max: 1 g daily.
Should be taken on an empty stomach. Take w/ a full glass of water on an empty stomach at least 1 hr before or 2 hr after meals.
Hypersensitivity to demeclocycline or other tetracyclines. Lactation. Concurrent use w/ methoxyflurane.
Special Precautions
Patients w/ pre-existing SLE and myasthenia gravis. Hepatic and renal impairment. Pregnancy.
Adverse Reactions
Photosensitivity, reversible nephrogenic diabetes insipidus, permanent discolouration of the teeth, brownish-black microscopic discolouration of thyroid tissue, nausea, vomiting, diarrhoea, increases in LFT values, hepatitis, jaundice, hepatic failure, rashes, pruritus, bullous dermatoses, exfoliative dermatitis, skin discolouration, pseudotumour cerebri in adults and bulging fontanelles in infants, headache, dizziness, visual disturbances, impaired hearing, urticaria, angioneurotic oedema, pericarditis, anaemia, thrombocytopenia, neutropenia, agranulocytosis, eosinophilia.
Potentially Fatal: Anaphylaxis, Stevens-Johnson syndrome, Clostridium difficile-associated disease.
Patient Counseling Information
Avoid direct exposure to sunlight or artificial UV light. May impair ability to drive and operate machinery.
Monitoring Parameters
Monitor CBC, plasma creatinine, renal and hepatic function.
Drug Interactions
Reduced absorption w/ antacids containing Al, Mg, or Ca, Fe-containing preparations, zinc, kaolin, quinapril, strontium ranelate, sucralfate, tripotassium dicitratobismuthate. May reduce the efficacy of oral contraceptives and penicillins. Increased risk of benign intracranial HTN w/ retinoids (e.g. acitretin, isotretinoin, tretinoin). Increased risk of ergotism w/ ergotamine and methysergide. May inactivate oral typhoid vaccine. May potentiate the effect of anticoagulants.
Potentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.
Food Interaction
Food, milk or dairy products reduce absorption of demeclocycline.
Description: Demeclocycline inhibits protein synthesis by binding w/ the 30S and possibly the 50S ribosomal subunits of susceptible bacteria. It may also cause alterations in the cytoplasmic membrane. It inhibits the action of antidiuretic hormone (ADH) in patients w/ chronic syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Onset: 2-5 days (SIADH).
Absorption: Approx 60-80% is absorbed from the GI tract. Food and milk reduce GI absorption by ≥50%. Time to peak plasma concentration: 3-4 hr.
Distribution: Crosses the placenta and enters breast milk. Volume of distribution: 1.7 L/kg. Plasma protein binding: 40-90%.
Metabolism: Not metabolised.
Excretion: Via urine and faeces as unchanged drug. Elimination half-life: Approx 12 hr.
Store between 20-25°C.
MIMS Class
Anon. Demeclocycline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 19/06/2014.

Buckingham R (ed). Demeclocycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. . Accessed 19/06/2014.

Declomycin (Demeclocycline hydrochloride) Tablets. U.S. FDA. Accessed 19/06/2014.

Demeclocycline HCl Tablet (CorePharma, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 19/06/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Demeclocycline Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 19/06/2014.

Disclaimer: This information is independently developed by MIMS based on Demeclocycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in